No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ETON Eton Pharmaceutical
- 3.280
- -0.120-3.53%
Close Jul 2 16:00 ET
- 3.380
- +0.100+3.05%
Post 19:34 ET
84.27MMarket Cap109.33P/E (TTM)
3.400High3.250Low18.82KVolume3.340Open3.400Pre Close62.57KTurnover0.09%Turnover RatioLossP/E (Static)25.69MShares5.81052wk High5.44P/B71.97MFloat Cap2.42052wk Low--Dividend TTM21.94MShs Float10.300Historical High--Div YieldTTM4.41%Amplitude1.950Historical Low3.324Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating
Craig-Hallum analyst Chase Knickerbocker maintains $Eton Pharmaceutical(ETON.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 42.6% and a total average return of 2.
Are Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) CEO For Now
Key Insights Eton Pharmaceuticals' Annual General Meeting to take place on 11th of June Salary of US$591.9k is part of CEO Sean Brynjelsen's total remuneration The overall pay is 103% above the in
Eton Pharmaceutical | 10-Q: Quarterly report
Express News | Eton Pharmaceuticals Inc: Q1 Revenue $8.0 Mln
Express News | Eton Pharmaceuticals Inc: Expects Continued Sales Growth to Result in Positive Operating Cash Flow Throughout Remainder of 2024
Comments
$Eton Pharmaceutical(ETON.US$ Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
-- Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13(th) straight quarter of sequential product sales growth
-- Acquired PKU GOLIKE(R), launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400
-- Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13(th) straight quarter of sequential product sales growth
-- Acquired PKU GOLIKE(R), launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400
$Eton Pharmaceutical(ETON.US$ Eton Pharmaceuticals Inc - Expects Et-400 and Alkindi Sprinkle(®) to Achieve Potential Combined Peak Sales of More Than $50 Mln Annually
1
2
$Eton Pharmaceutical(ETON.US$ Eton Pharmaceuticals Acquires Exclusive U.S. Rights To PKU GOLIKE From Relief Therapeutics, Expects To Be Accretive To Earnings In 2024
Moomoo 24/7· 02:29
Eton Pharmaceutical PKU GOLIKE is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point
Transaction is expected to be accretive to 2024 earnings
Estimated peak sales of more than $10 million annually
U.S. phenylketonur...
Moomoo 24/7· 02:29
Eton Pharmaceutical PKU GOLIKE is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point
Transaction is expected to be accretive to 2024 earnings
Estimated peak sales of more than $10 million annually
U.S. phenylketonur...
1
$Eton Pharmaceutical(ETON.US$ Thu, 14 March 2024 at 5:35 PM GMT-4
• Revenue Growth: Q4 product sales and royalty revenue surged by 109% year-over-year to $7.3 million.
• Positive Cash Flow: ETON generated $0.4 million in operating cash flow in Q4, with a cash reserve of $21.4 million.
• Research and Development: R&D expenses slightly increased to $1.0 million in Q4, supporting progress in the company's drug pipeline.
• Net Loss: ETON reported a net loss of $2.3 million in Q4...
• Revenue Growth: Q4 product sales and royalty revenue surged by 109% year-over-year to $7.3 million.
• Positive Cash Flow: ETON generated $0.4 million in operating cash flow in Q4, with a cash reserve of $21.4 million.
• Research and Development: R&D expenses slightly increased to $1.0 million in Q4, supporting progress in the company's drug pipeline.
• Net Loss: ETON reported a net loss of $2.3 million in Q4...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg